Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 36004199)

  • 1. Short-term outcome of neoadjuvant immunotherapy and chemotherapy in non-small cell lung cancer: A systematic review and meta-analysis.
    Zhang C; Hong HZ; Wu YL; Zhong WZ
    JTCVS Open; 2021 Dec; 8():588-607. PubMed ID: 36004199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant Chemo-Immunotherapy for Early-Stage Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Banna GL; Hassan MA; Signori A; Giunta EF; Maniam A; Anpalakhan S; Acharige S; Ghose A; Addeo A
    JAMA Netw Open; 2024 Apr; 7(4):e246837. PubMed ID: 38625698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials.
    Zhang W; Liang Z; Zhao Y; Li Y; Chen T; Li W; Chen Y; Wu P; Zhang H; Fang C; Li L
    Front Immunol; 2024; 15():1359302. PubMed ID: 38646542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant immunotherapy for advanced, resectable non-small cell lung cancer: A systematic review and meta-analysis.
    Wu Y; Verma V; Gay CM; Chen Y; Liang F; Lin Q; Wang J; Zhang W; Hui Z; Zhao M; Wang J; Chang JY
    Cancer; 2023 Jul; 129(13):1969-1985. PubMed ID: 36994945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC: An Indirect Meta-Analysis.
    Zhou Y; Li A; Yu H; Wang Y; Zhang X; Qiu H; Du W; Luo L; Fu S; Zhang L; Hong S
    JAMA Netw Open; 2024 Mar; 7(3):e241285. PubMed ID: 38451524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant Immunotherapy and Non-Small Cell Lung Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Yu S; Zhai S; Gong Q; Xiang C; Gong J; Wu L; Pu X
    Am J Clin Oncol; 2023 Nov; 46(11):517-528. PubMed ID: 37749786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is neoadjuvant immunotherapy necessary in patients with programmed death ligand 1 expression-negative resectable non-small cell lung cancer? A systematic review and meta-analysis.
    Zhang SL; Tian Y; Yu J; Zhang JH; Sun L; Huang LT; Ma JT; Han CB
    Lung Cancer; 2024 May; 191():107799. PubMed ID: 38669725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer: a systematic review and meta-analysis.
    Jiang J; Wang Y; Gao Y; Sugimura H; Minervini F; Uchino J; Halmos B; Yendamuri S; Velotta JB; Li M
    Transl Lung Cancer Res; 2022 Feb; 11(2):277-294. PubMed ID: 35280319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Clinical and Safety Outcomes of Neoadjuvant Immunotherapy Combined With Chemotherapy for Patients With Resectable Esophageal Cancer: A Systematic Review and Meta-analysis.
    Ge F; Huo Z; Cai X; Hu Q; Chen W; Lin G; Zhong R; You Z; Wang R; Lu Y; Wang R; Huang Q; Zhang H; Song A; Li C; Wen Y; Jiang Y; Liang H; He J; Liang W; Liu J
    JAMA Netw Open; 2022 Nov; 5(11):e2239778. PubMed ID: 36322089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant immunotherapy combined with chemotherapy significantly improved patients' overall survival when compared with neoadjuvant chemotherapy in non-small cell lung cancer: A cohort study.
    Dai F; Wu X; Wang X; Li K; Wang Y; Shen C; Zhou J; Niu H; Deng B; Tan Q; Wang R; Guo W
    Front Oncol; 2022; 12():1022123. PubMed ID: 36353552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of neoadjuvant chemo-immunotherapy in non-small cell lung cancer: a real-world, multicenter, retrospective study.
    Wang X; Wang X; Hui B; Cai J; Zhao H; Qiao B; Duan J; Chen K; Wang J; Lei J; Yang F
    Transl Lung Cancer Res; 2024 Apr; 13(4):849-860. PubMed ID: 38736498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant PD-1/PD-L1 Inhibitors for Resectable Head and Neck Cancer: A Systematic Review and Meta-analysis.
    Masarwy R; Kampel L; Horowitz G; Gutfeld O; Muhanna N
    JAMA Otolaryngol Head Neck Surg; 2021 Oct; 147(10):871-878. PubMed ID: 34473219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy in potentially resectable stage IIIA/IIIB non-small cell lung cancer: Neo-Pre-IC, a single-arm phase 2 trial.
    Sun C; Wang X; Xu Y; Shao G; Chen X; Liu Y; Zhang P; Lin X; Ma X; Qiu S; He H; Yang Z; Ma K
    EClinicalMedicine; 2024 Feb; 68():102422. PubMed ID: 38304743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining neoadjuvant chemotherapy with PD-1/PD-L1 inhibitors for locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis.
    Yuan Z; Cui H; Wang S; Liang W; Cao B; Song L; Liu G; Huang J; Chen L; Wei B
    Front Oncol; 2023; 13():1103320. PubMed ID: 36776290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant Immunotherapy Improves Treatment for Early Resectable Non-Small-Cell Lung Cancer: A Systematic Review and Meta-analysis.
    Dong P; Yan Y; Yang L; Wu D; Wang H; Lv Y; Zhang J; Yu X
    J Oncol; 2022; 2022():2085267. PubMed ID: 36213828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world outcomes of immunotherapy-based neoadjuvant therapy in resectable non-small cell lung cancer.
    Shen J; Gu L; Qi Y; Yao Y; Lu S; Chen Z
    Front Immunol; 2023; 14():1268251. PubMed ID: 37818382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 expression and Tumor mutation burden as Pathological response biomarkers of Neoadjuvant immunotherapy for Early-stage Non-small cell lung cancer: A systematic review and meta-analysis.
    Deng H; Zhao Y; Cai X; Chen H; Cheng B; Zhong R; Li F; Xiong S; Li J; Liu J; He J; Liang W
    Crit Rev Oncol Hematol; 2022 Feb; 170():103582. PubMed ID: 35031441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review and meta-analysis of neoadjuvant chemoimmunotherapy in stage III non-small cell lung cancer.
    Liu W; Zhang T; Zhang Q; Li L; Xu C
    BMC Pulm Med; 2022 Dec; 22(1):490. PubMed ID: 36582007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review.
    Zhao Z; Gao Y; Xue Q; Gao S; He J
    Target Oncol; 2021 Jul; 16(4):425-434. PubMed ID: 33983556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant immunotherapy and neoadjuvant chemotherapy in resectable non-small cell lung cancer: A systematic review and single-arm meta-analysis.
    Wang H; Liu T; Chen J; Dang J
    Front Oncol; 2022; 12():901494. PubMed ID: 36212419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.